ArticlePloS one2022

Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events.

Tigran Makunts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.